UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
 and NASH to be Rescheduled - EconoTimes)
LIVONIA, Mich., Feb. 27, 2018 -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia, non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), today announced that due to a family emergency of one of the a panel members, it will need to reschedule the expert panel call discussing pediatric nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) that was scheduled for Wednesday, February 28. A new date and time for the expert panel call will be announced as soon as possible.
About Gemphire
Gemphire is a clinical-stage biopharmaceutical company that is committed to helping patients with cardiometabolic disorders, including dyslipidemia and NASH. The Company is focused on providing new treatment options for cardiometabolic diseases through its complementary, convenient, cost-effective product candidate gemcabene as add-on to the standard of care, especially statins, that will benefit patients, physicians, and payors. Gemphire’s Phase 2 clinical program is evaluating the efficacy and safety of gemcabene in hypercholesterolemia, including FH and ASCVD, SHTG and NASH/NAFLD. Two trials supporting hypercholesterolemia have been completed under NCT02722408 and NCT02634151. Gemphire has completed recruitment for a clinical trial for SHTG under NCT02944383, and has initiated separate trials for adult NASH and pediatric NAFLD. Please visit www.gemphire.com for more information.
Contact:
Andrew McDonald, Ph.D.
LifeSci Advisors, LLC
(646) 597-6987
Jeff Mathiesen, CFO
Gemphire Therapeutics Inc.
(734)-245-1700
